Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-68736-2
Affiliations:
6
Authors:
14
Go to article
Institutions Authors Share
Shanghai Ninth People's Hospital, SJTU, China
14.000000
14.000000
 1.00
Interested in Oncology and Carcinogenesis?